Company / Shareholders' Equity
INOVIO PHARMACEUTICALS, INC. Shareholders' Equity History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$68.5M
FY2025
5-year range
$68.5M / $461.1M
FY2021-FY2025
Trend
-41.6%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Shareholders' Equity has declined for 4 consecutive years, from $461M in FY2021 to $69M in FY2025.
Based on SEC 10-K filings.
$69M in FY2025 with a 5-year CAGR of -31.7%.
Declined from $222M to $69M over the past 2 years.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -44.5%
- 5-Year CAGR
- -31.7%
- 10-Year CAGR
- -
Key checks
Key Insights
- INOVIO PHARMACEUTICALS, INC.'s shareholders' equity has declined for 4 consecutive years.
- 5-year CAGR of -31.7%, indicating a declining trend.
- In FY2025, shareholders' equity decreased 41.6% year-over-year.
- Peak shareholders' equity was recorded in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 0.43 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $68.5M | -41.6% |
| FY2024 | $117.3M | -47.2% |
| FY2023 | $222.4M | -44.4% |
| FY2022 | $399.7M | -13.3% |
| FY2021 | $461.1M | +0.0% |
| FY2020 | $461.1M | +13324.4% |
| FY2019 | $3.4M | -96.0% |
| FY2018 | $86.9M | -38.9% |
| FY2017 | $142.4M | +15.5% |
| FY2016 | $123.3M | -29.8% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026